Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stevanato Group SpASTVN -0.93%86 EV-to-OCF is 20.61 as of Sep. 09, 2026, which is 42% below its 10-year median of 35.69. GuruFocus rates STVN with a GF Score™ of 86/100 and a GF Value™ of $26.04 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Stevanato Group SpA ranks worse than 76% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Stevanato Group SpA's Enterprise Value is $5,968 Mil.
Stevanato Group SpA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $290 Mil. Therefore, Stevanato Group SpA's EV-to-OCF for today is 20.61.
The historical rank and industry rank for Stevanato Group SpA's EV-to-OCF or its related term are showing as below:
STVN'
s EV-to-OCF Range Over the Past 10 Years
Min: 12.49 Med: 35.69 Max: 80.78
Current: 20.61
During the past 8 years, the highest EV-to-OCF of Stevanato Group SpA was 80.78. The lowest was 12.49. And the median was 35.69.
STVN's EV-to-OCF is ranked worse than 76% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 7.895
vs STVN: 20.61
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stevanato Group SpA (NYSE:STVN) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stevanato Group SpA's PE Ratio (TTM) for today is calculated as:
Stevanato Group SpA's share price for today is $20.32.
Stevanato Group SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.560.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Stevanato Group SpA EV-to-OCF Related Terms
Stevanato Group SpA EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Stevanato Group SpA's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Stevanato Group SpA's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stevanato Group SpA EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SpA's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Stevanato Group SpA's EV-to-OCF falls into.
Stevanato Group SpA's current Enterprise Value is $5,968 Mil.
Stevanato Group SpA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $290 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stevanato Group SpA (STVN) has a EV-to-OCF of 20.61 as of Sep. 09, 2026. This is 42% below median its historical median of 35.69. Over the past decade, Stevanato Group SpA's EV-to-OCF has ranged from 12.49 to 80.78. According to the industry distribution chart, Stevanato Group SpA ranks #646 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 76%.
Is Stevanato Group SpA's EV-to-OCF too high?
Stevanato Group SpA's current EV-to-OCF of 20.61 is 42% below median its 10-year median of 35.69. Over the past 10 years, this metric has ranged from a low of 12.49 to a high of 80.78. The Medical Devices & Instruments industry median EV-to-OCF is 7.90. Stevanato Group SpA's value of 20.61 is 161.1% above this industry median. Based on the distribution chart, Stevanato Group SpA ranks #646 out of 850 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Stevanato Group SpA has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stevanato Group SpA's EV-to-OCF compare to MMED and TFX?
According to the Medical Devices & Instruments industry distribution chart, Stevanato Group SpA ranks #646 out of 850 companies for EV-to-OCF. This places Stevanato Group SpA in the lower half of its industry. The industry median EV-to-OCF is 7.90. Stevanato Group SpA's value of 20.61 is 161.1% above this benchmark. Historically, Stevanato Group SpA's own EV-to-OCF has ranged from 12.49 to 80.78 over the past decade. While the company's 10-year median is 35.69 vs. the industry median of 7.90, Stevanato Group SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.90, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stevanato Group SpA's current EV-to-OCF of 20.61 is 161.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stevanato Group SpA's current EV-to-OCF is 20.61, which is 42% below median its own 10-year median of 35.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stevanato Group SpA stock overvalued right now?
Based on GuruFocus' analysis, Stevanato Group SpA (STVN) is currently considered Modestly Undervalued. The stock's GF Value™ is $26.04, compared to a current price of $20.32 — trading 22% below its estimated fair value. The current EV-to-OCF is 20.61, which is 42% below median its 10-year median of 35.69 and 161.1% above the Medical Devices & Instruments industry median of 7.90. Stevanato Group SpA's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Stevanato Group SpA (STVN), the current EV-to-OCF is 20.61 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stevanato Group SpA (STVN) Overvalued in 2026?
Based on GuruFocus' analysis, Stevanato Group SpA stock appears to be undervalued.
The current stock price of $20.32 is trading 22% below its estimated GF Value™ of $26.04.
GuruFocus considers Stevanato Group SpA to be Modestly Undervalued.
Key valuation signals for STVN:
EV-to-OCF: 20.61 (42% below median its 10-year median of 35.69)
GF Value™: $26.04 vs. price of $20.32 (22% below fair value)
Industry Position: 161.1% above the Medical Devices & Instruments median (#646 of 850)
No single metric tells the full story. See the STVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
86GF Score
Get the complete analysis for STVN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STVN has been successfully added to your 
